Home Cart Sign in  
Chemical Structure| 58546-54-6 Chemical Structure| 58546-54-6

Structure of Schisandrol B
CAS No.: 58546-54-6

Chemical Structure| 58546-54-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Schisandrol B (Gomisin-A) is the principal active ingredient of Schisandra chinensis, known for its hepatoprotective effects. It inhibits the generation of reactive oxygen species (ROS) and the activity of P-glycoprotein and CYP3A, while also exhibiting anti-inflammatory, anti-diabetic, and antioxidant properties.

Synonyms: Gomisin A; TJN-101; Wuweizichun B

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Schisandrol B

CAS No. :58546-54-6
Formula : C23H28O7
M.W : 416.46
SMILES Code : C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C[C@]1(C)O)OC)OC)OC)OC)OCO3
Synonyms :
Gomisin A; TJN-101; Wuweizichun B
MDL No. :MFCD01941645

Safety of Schisandrol B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse liver microsomes 2.5, 5, 10, 20, 40, 80 µM 10 minutes To evaluate the inhibitory effect of SolB on APAP metabolic activation, results showed that SolB significantly inhibited the formation of NAPQI-GSH in a dose-dependent manner. Toxicol Sci. 2015 Jan;143(1):107-15
MCF-7 cells 25 µM, 50 µM, 100 µM 144 hours To evaluate the effect of Schisandrol B on the proliferation of MCF-7 cells. Results showed that Schisandrol B significantly promoted the proliferation of MCF-7 cells. Pharmaceutics. 2021 Jul 15;13(7):1082
LO-2 cells 5, 10, 20, 40 µM 24 hours To evaluate the protective effect of Schisandrol B on APAP-induced hepatocyte injury. Results showed that Schisandrol B dose-dependently improved cell viability and inhibited LDH release. Front Pharmacol. 2021 Jun 3;12:655531.
INS-1 cells 1 µM, 2.5 µM, 5 µM 24 hours To evaluate the effect of Schisandrol B on glucose-stimulated insulin secretion in INS-1 cells, results showed that Schisandrol B had no significant effect on GSIS. Molecules. 2021 Oct 28;26(21):6509
HK-2 cells 10 µM 24 hours To evaluate the protective effect of Schisandrol B on UA-injured HK-2 cells, results showed that Schisandrol B significantly improved cell viability and inhibited cell apoptosis. Front Pharmacol. 2025 Apr 29;16:1563676
Huh7 cells 2.5, 10, and 40 µM 24 hours To evaluate the effect of SolB on PXR-regulated gene expression. Results showed that SolB exhibited similar inducible effects on target genes in Huh7 cells as in HepG2 cells. Br J Pharmacol. 2017 Apr;174(8):672-688
HepG2 cells 2.5, 10, and 40 µM 24 hours To evaluate the effect of SolB on PXR-regulated gene expression. Results showed that SolB significantly and dose-dependently increased CYP3A4, UGT1A1, and OATP2 mRNA levels. Br J Pharmacol. 2017 Apr;174(8):672-688
HEK293T cells 2.5, 10, and 40 µM 24 hours To evaluate the effect of SolB on hPXR reporter gene activity. Results showed that SolB concentration-dependently enhanced hPXR reporter gene activity by 3.6-fold at 40μM. Br J Pharmacol. 2017 Apr;174(8):672-688
HepG2 cells 2.5-20 µM 24 hours To evaluate the effect of SolB on NRF2 activation, results showed that SolB dose-dependently increased the luciferase activity of the NRF2 reporter gene. Acta Pharmacol Sin. 2016 Mar;37(3):382-9
CYP3A5*3/*3 genotyped HLMs 0-8 µM 30 minutes Evaluate TDI of SZB on CYP3A4, showing kinact=0.37 min-1, KI=0.69 μM Int J Mol Sci. 2022 Apr 19;23(9):4485
CYP3A5*1/*3 genotyped HLMs 0-16 µM 30 minutes Evaluate TDI of SZB on CYP3A5, showing kinact=0.009 min-1, KI=0.5 μM Int J Mol Sci. 2022 Apr 19;23(9):4485
Human liver microsomes (HLMs) 0-20 µM 30 minutes Determine IC50 of SZB on CYP3A, showing time-dependent inhibition (IC50 shift=21.39) Int J Mol Sci. 2022 Apr 19;23(9):4485
Human liver microsomes (HLM) 0.5-25 µM 60 minutes To evaluate the reversible inhibition of Schisandrol B on CYP2C8-mediated metabolism of imatinib. Results showed that Schisandrol B strongly reversibly inhibited CYP2C8 enzyme. Br J Clin Pharmacol. 2020 Oct;86(10):2080-2094
Recombinant CYP3A4 enzyme 0.5-25 µM 60 minutes To evaluate the reversible inhibition of Schisandrol B on CYP3A4-mediated metabolism of imatinib and bosutinib. Results showed that Schisandrol B reversibly inhibited CYP3A4-mediated metabolism of imatinib and bosutinib. Br J Clin Pharmacol. 2020 Oct;86(10):2080-2094

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice APAP-induced hepatotoxicity model Oral 12.5, 50, 200 mg/kg/d 7 administrations with 12-hour intervals To evaluate the protective effect of SolB against APAP-induced hepatotoxicity, results showed that SolB significantly reduced ALT and AST activities and decreased liver necrosis and hemorrhage in a dose-dependent manner. Toxicol Sci. 2015 Jan;143(1):107-15
C57BL/6 mice Acetaminophen (APAP)-induced acute hepatotoxicity model Gavage 200 mg/kg/d Every 12 hours, 7 times, for 3 days To evaluate the protective effect of SolB against APAP-induced hepatotoxicity, results showed that SolB pretreatment significantly alleviated liver injury, increased nuclear accumulation of NRF2 and its downstream protein expression. Acta Pharmacol Sin. 2016 Mar;37(3):382-9
SD rats Allergic asthma model Gavage 3.09 g/kg, 1.54 g/kg, and 0.77 g/kg Once daily for 28 days To evaluate the therapeutic effect of Schisandrol B on allergic asthma, the results showed that WSC was more effective than RSC at the same dose. Chin Med. 2023 Jan 30;18(1):10
C57BL/6 mice BDL and CCl4-induced hepatic fibrosis models Gavage 40 mg/kg Once daily for 14 days To evaluate the inhibitory effect of Schisandrol B on BDL and CCl4-induced hepatic fibrosis. Results showed that Schisandrol B significantly alleviated hepatic injury and fibrosis and inhibited the expression of α-SMA. Front Pharmacol. 2021 Jun 3;12:655531.
C57BL/6J mice LCA-induced intrahepatic cholestasis model Oral 6.25, 25, and 100 mg/kg Twice daily for 7 days To evaluate the protective effect of SolB against LCA-induced cholestatic liver injury. Results showed that SolB dose-dependently reversed LCA-induced increases in ALT, AST, and ALP, and significantly reduced serum TBA and Tbili levels. Additionally, SolB treatment significantly decreased mortality in cholestatic mice. Br J Pharmacol. 2017 Apr;174(8):672-688

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.01mL

2.40mL

1.20mL

24.01mL

4.80mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories